Dual Targeted Therapy with p53 siRNA and Epigallocatechingallate in a Triple Negative Breast Cancer Cell Model

Cornelia Braicu¹, Valentina Pileczki¹, Laura Pop¹, Roxana Cojocneanu Petric¹,³, Sergiu Chira¹, Eve Pointiere⁴, Patriciu Achimas-Cadariu⁵,⁶*, Ioana Berindan-Neagoe¹,⁷,⁸,⁹*

¹ Research Center for Functional Genomics, Biomedicine and Translational Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania, ² Faculty of Pharmacy, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania, ³ Faculty of Biology and Geology, Babeș-Bolyai University, Cluj-Napoca, Romania, ⁴ Haute École Louvain en Hainaut, Fleurus, Belgique, ⁵ Department of Surgery, The Oncology Institute ”Prof Dr. Ion Chiricuta”, Cluj-Napoca, Romania, ⁶ Department of Surgical Oncology and Gynaecological Oncology, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania, ⁷ Department of Immunology, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania, ⁸ Department of Functional Genomics and Experimental Pathology, The Oncology Institute ”Prof Dr. Ion Chiricuta”, Cluj-Napoca, Romania, ⁹ Department of Experimental Therapeutics M.D. Anderson Cancer Center Houston, Texas, United States of America

* ioananeagoe29@gmail.com (IBN); pachimas@umcluj.ro (PAC)

Abstract

Triple-negative breast cancer (TNBC) is a highly aggressive phenotype that is resistant to standard therapy. Thus, the development of alternative therapeutic strategies for TNBC is essential. The purpose of our *in vitro* study was to evaluate the impact of p53 gene silencing in conjunction with the administration of a natural compound, epigallocatechingallate (EGCG). RT²Profiler PCR Array technology was used to evaluate the impact of dual treatment on the main genes involved in apoptosis in the Hs578T cell culture model of TNBC. Gene expression analysis revealed 28 genes were significantly altered (16 upregulated and 12 downregulated) in response to combined p53 siRNA and EGCG treatment. Further analysis revealed that p53 siRNA and EGCG dual therapy leads to the activation of pro-apoptotic genes and the inhibition of pro-survival genes, autophagy, and cell network formation. These results indicate that this dual therapy targets both the apoptotic and angiogenic pathways, which may improve treatment effectiveness for tumors resistant to conventional treatment.

Introduction

Of all cancers, breast cancer has the highest incidence and mortality rate in Europe according to data from 2012 [1]. Approximately 15–20% of breast cancer cases are diagnosed as triple-negative breast cancer (TNBC), a highly aggressive clinical phenotype characterized by a lack of human epidermal growth factor receptor-2 (HER-2) overexpression, as well as a lack of
estrogen and progesterone receptor expression [2, 3]. The overall survival rate of TNBC is less than 30% at five years after diagnosis due to its unique histological and molecular features, as well as the ineffectiveness of treatments and adjuvant hormone therapies [4]. TNBC represents a hostile histological subtype of breast cancer with limited medication options; therefore the development of alternative targeted therapies is important to improve the overall survival rates of TNBC patients [5].

The p53 gene, i.e. the ‘rebel angel’ according to Walerych [6], is the most frequently mutated gene in the pathology of breast cancer tumors [7]. Mutant p53 has an oncogenic role in tumorigenesis and metastasis [6]. The p53 protein is overexpressed in TNBC and is involved in the cellular stress response, repair and survival of damaged cells, and cell cycle arrest, as well as resistance to apoptosis and inhibition of autophagy [6, 9, 10]. Increasing evidence shows that the p53 mutation is related to the activation of invasion and metastasis, as well as to inhibition of angiogenesis [6, 11], suggesting therapies involving p53 siRNA may target multiple molecular mechanisms as well as apoptosis [12].

Epigallocatechingallate (EGCG) is the most abundant compound found in green tea, and many research studies, in the last decade, have focused on its biological activities and mechanisms of action in cancer. EGCG inhibits several critical proteins that are involved in cancer cell progression [13], migration [14], and induction of apoptosis through the production of reactive oxygen species, induction of cell cycle progression, and inhibition of the NF-κB cell-signaling pathway [15].

To identify the physiological responsiveness of EGCG in tumor breast cancer cells, elucidating the molecular mechanisms and the molecular targets that trigger or inhibit a specific signaling pathway is essential [16]. In the present study, we investigated the response of in vitro breast cancer cells to multiple therapeutic targets by silencing mutant p53 through RNA interference mechanisms and investigating the inhibitory effect of EGCG on tumor cell survival, growth, and migration, and thereby the mechanism of treatment resistance using dual targeted therapy.

Materials and Methods

Cell culture

We purchased the TNBC cell line Hs578T, which expresses a mutant p53 gene, from the American Type Culture Collection for all experiments. Cells were maintained in high-glucose DMEM containing 10% fetal bovine serum, 2 mM L-glutamine, and 2 mM penicillin-streptomycin (all from Sigma-Aldrich, Germany) supplemented with 0.1% insulin. Cells were incubated in 5% CO₂ incubator at 37°C.

siRNA transfection

For mRNA analysis, cells were plated in 6-well plates at a seeding density of 5 × 10⁵ cells and simultaneously transfected, alone or in combination with 40 nmol p53-siRNA (Ambion, TX, USA) and EGCG (Sigma-Aldrich, St. Louis, MO, USA). The siPORT NeoFX Transfection Agent (Invitrogenby Life Technologies) being used for siRNA delivery, and cells were cultured in Opti-MEM I (Gibco-Invitrogen, Paisley, UK) reduced serum medium. Cells were harvested in TriReagent (Sigma-Aldrich, St. Louis, MO, USA) 24 hours after transfection and prepared for total RNA extraction. For autophagy and angiogenesis assays, we used 96-well plates and reduced the reagent volumes by one-tenth. All experiments being performed in triplicate.
RNA extraction, qRT-PCR array and data analysis

Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) and reverse transcribed to cDNA using RT2 First Strand Kit protocol according to the manufacturer’s instructions. A total of 102 μL cDNA were used for each Human Apoptosis RT2Profiler PCR Array plate. A reaction volume of 25 μL/well of RT2 SYBR Green Master mix with the appropriate RT2 Profiler Pathway “Signature” PCR Array was used according to manufacturer’s instructions. Gene expression assessment was done using Apoptosis PCR Array (PAHS-012Z), based on a standard protocol from Qiagen.

Gene expression was analyzed from three different experiments based on the ΔΔCt method using PCR array data analysis software from SABioscience [17] (http://www.sabiosciences.com/pcrarraydataanalysis.php). Genes with a fold change ≤-1.5 or ≥1.5 were considered to be genes of interest. The Ingenuity System Pathway Analysis program was used to interpret and integrate the experimental data into biological networks.

In vitro angiogenesis assay

We used the In Vitro Angiogenesis Assay Kit from Cayman Chemical (Cayman, USA) according to the manufacturer’s instructions with the following modifications. Plates were coated with 35 μl Cell-Based Extracellular Matrix Gel and incubated for 2 hours at 37°C to allow the gel to solidify before cell seeding. The cell network formation was evaluated under an inverted fluorescent microscope with filter for excitation at 485 nm and emission at 535 nm.

Autophagy/cytotoxicity evaluation

We used the Autophagy/Cytotoxicity Dual Staining Kit (Cayman Europe, Estonia) according to the manufacturer’s protocol for both fluorescence microscopy and plate reader fluorescence detection. Plates were analyzed using a fluorescent microscope and a plate reader at excitation/emission wavelengths of 540/570 nm for propidium iodide and 350/520 nm for monodansylcadaverine detection, respectively.

Results

Gene expression data analysis

Using qRT-PCR array technology, we examined the transcript levels of 84 genes involved in apoptosis from the Hs578T-cell line transfected with p53 siRNA and incubated with EGCG. Relative quantification of the transcripts using the 2-ΔΔCT method revealed 16 genes that were upregulated and 12 genes were downregulated in response to the combined treatment of p53 siRNA cells with EGCG (Table 1 and Figs 1 and 2).

Upon further analysis, we showed that the increases in gene expression occurred primarily in the Bcl-2 and tumor necrosis factor receptor superfamilies, which are associated with activation of apoptotic mechanisms (Table 1 and Fig 1). By contrast, the BIRC family members, which inhibit apoptosis by preventing the proteolysis of procaspase-3, procaspase-6, and procaspase-7, were downregulated.

Angiogenesis and autophagy/cytotoxicity evaluation

Figs 3 and 4 show the effect of p53 gene knockdown and combined treatment with EGCG in blocking angiogenesis and autophagy. Hs578T cell network formation was significantly reduced in the cells treated with EGCG for 24 and 48 h, respectively, compared with control-treated cells.
Most studies of TNBC are focused on the identification of novel chemotherapeutics targeting pathways involved in angiogenesis, growth, survival, or activation of apoptosis [3–5, 6]. Because TNBC has a highly heterogeneous pathology, most studies address the idea of combined therapy. The purpose of our study was to investigate whether combined treatment with p53 siRNA and EGCG increased apoptosis in the TNBC cancer cell line, Hs578T. Using PCR array approach, we showed that EGCG altered gene expression and promote apoptosis, decrease cell survival, and reduce angiogenesis and autophagy in cells with p53 siRNA. These findings may provide insight on genetic-based approaches for treating TNBC based on the specific activation of pro-apoptotic genes and inhibition of pro-survival genes in response to combined treatment with p53 siRNA and EGCG. Our findings suggest that the combined p53 siRNA and EGCG treatment increased apoptosis more than either of these treatments alone, which may contribute to increased TNBC cell death.

Table 1. Genes that were found to be statistically significant in the experiment, classified by their fold regulation and stimulation/inhibition of genes involved in apoptosis pathway.

| Gene                                    | Gene Symbol | Fold Regulation |
|-----------------------------------------|-------------|----------------|
| Harakiri, BCL2 interacting protein      | HRK         | 4.7327 ***     |
| (contains only BH3 domain)              |             |                |
| PYD and CARD domain containing          | PYCARD      | 4.3853 *       |
| CD40 ligand                             | CD40LG      | 3.3932 **      |
| BCL2-like 10                            | BCL2L10     | 3.3932 **      |
| Caspase 5, apoptosis-related cysteine   | CASP5       | 3.3932 **      |
| peptidase                               |             |                |
| Fas ligand (TNF superfamily, member 6)  | FASLG       | 3.0723 **      |
| CD40 molecule, TNF receptor superfamily| CD40        | 2.9201 *       |
| member 5                                | TNFRSF1A    | 2.5597 ***     |
| Tumor necrosis factor receptor          | TNFSF8      | 2.4612 **      |
| superfamily, member 1A                  |             |                |
| Tumor necrosis factor (ligand)          | TNFRSF11B   | 1.5967 *       |
| superfamily, member 11b                 |             |                |
| Caspase recruitment domain family,      | CARD6       | 2.1525 **      |
| member 6                                |             |                |
| BCL2-associated athanogene 3            | BAG3        | 2.0411 **      |
| Lymphotixin beta receptor (TNFR         | LTBR        | 1.8782 **      |
| superfamily)                            |             |                |
| BCL2-associated agonist of cell death   | BAD         | 1.6464 *       |
| BCL2-antagonist/killer 1                | BAK1        | 1.6388 *       |
| Tumor necrosis factor receptor          | TNFRSF11B   | 1.5967 *       |
| superfamily, member 11b                 |             |                |
| Fas (TNF receptor superfamily, member   | FAS         | -1.5627 *      |
| 6)                                      |             |                |
| NLR family, apoptosis inhibitory protein| NAIP        | -1.6253 *      |
| BCL2-like 2                             | BCL2L2      | -1.6029 *      |
| Baculoviral IAP repeat containing 6     | BIRC6       | -1.8117 *      |
| v-raf murine sarcoma viral oncogene     | BRAF        | -1.9062 ***    |
| homolog B1                              |             |                |
| Baculoviral IAP repeat containing 2     | BIRC2       | -1.9239 ***    |
| Insulin-like growth factor 1 receptor   | IGF1R       | -1.9734 ***    |
| Baculoviral IAP repeat containing 3     | BIRC3       | -2.1053 ***    |
| Tumor necrosis factor receptor superfamily, member 21 | TNFRSF21 | -2.2408 * |
| Caspase recruitment domain family,      | CARD8       | -2.6647 *      |
| member 8                                |             |                |
| Tumor protein p53                        | TP53        | -3.2058 ***    |
| Tumor necrosis factor receptor          | TNFRSF25    | -3.965 *       |
| superfamily, member 25                  |             |                |

*P-value <0.01
**P-value <0.001
***P-value <0.0001

doi:10.1371/journal.pone.0120936.t001
Increasing evidence has shown that expression of the p53 gene is related to breast cancer prognosis [3, 6, 18]. A previous study on HeLa cells shows that cancer therapy using p53 siRNA specifically triggers apoptotic mechanisms [19, 20, 21], and increases the efficiency of other therapeutic agents by increasing the sensitivity of cancer cells to apoptosis [20].

The p53 protein is an important mediator of various cellular processes, such as modulation of senescence, apoptosis, and cell cycle genes [6, 7]. Recent clinical trials have demonstrated the role of p53 siRNA and the efficacy of RNA interference-based drugs in general in anticancer therapy [22, 23], although the precise transcriptional mechanisms by which p53 siRNA initiates and supports apoptosis still need to be clarified. The extrinsic signaling pathway of apoptosis is based on the activation of so-called ‘death receptors,’ whereas the intrinsic mechanism is activated by modifications in DNA structure. After the mitochondrial membrane is depolarized, cytochrome c is released into the cytoplasm from the intermembrane space of the mitochondria. The result of both extrinsic and intrinsic pathways is the activation of caspases and ultimately cell death [6, 7]. p53 increase the recovery of cells damaged by therapy, thus acting as a survival factor to prevent mitotic catastrophe and to provide a basis for dual therapies [24].

One possible mechanism by which the two apoptotic pathways converge is based on the synergistic effect of p53 together with the administration of EGCG or other therapeutic compounds. Similar to our previous findings [25], combined p53 siRNA and EGCG treatment minimized the activation of the anti-apoptotic genes (such as BAG3, XIAP, and RIPK2) related to treatment resistance, which may further increase cancer cell sensitivity to treatment.

Along with the present study, recent experimental studies have shown that inhibition of autophagy or Fas signaling may be novel therapeutic targets for TNBC therapy [26]. In addition, inhibition of autophagy increased the therapeutic response in anthracycline-sensitive and-resistant TNBC, emphasizing the importance of this mechanism in drug resistance [27]. The inhibition of autophagy shifts the expression of the p53 protein, Bcl-2 family proteins, and the ratio of Bax/Bcl-xL proteins, which promotes apoptosis in MDA-MB-231 cells (a TNBC model similar to Hs578T) [28].

Our previous studies show that EGCG suppresses migration and invasion of TNBC cells [29]. We confirmed this in the present study with the evaluation of the cell network formation and the activation of drug resistance genes [25]. Therefore, the combination of p53 siRNA and
EGCG may also increase efficacy of treatment by inhibiting cell network formation and activating autophagy.

Multi-targeted therapy optimizes efficacy of anti-tumor treatment. These data may be particularly useful in TNBC, a form of breast cancer that is highly resistant to current cancer therapies and has an average survival rate of less than three years. Therefore, our proposed treatment is particularly advantageous because it specifically targets anti-apoptotic, anti-angiogenic, and anti-autophagic mechanisms of these cancer cells.

**Conclusion**

Comprehension of how a particular therapeutic combination affects every tumor compartment paves the way for the discovery of novel drugs or therapeutic strategies. Our preliminary results
showed that combining EGCG with p53 siRNA enhanced the antitumoral effect on the TNBC cancer cell line, by specifically activation of apoptosis and autophagy.

This study provides novel insight on new multifaceted breast cancer therapies that target a genetic component, such as the overexpression of mutant p53, and administer in conjunction with a natural compounds such as EGCG.

**Supporting Information**

S1 Data Set. PCR-array raw data. (XLS)

**Acknowledgments**

This work was financed by the Sectoral Operational Program for Increasing the Economic Competitiveness (POSCE) 709/2010 grant with the title: “Clinical and economical impact of proteome and transcriptome molecular profiling in neoadjuvant therapy of triple-negative breast cancer (BREASTIMPACT)”. Cornelia Braicu has received a research grant financed by THE NATIONAL PLAN FOR RESEARCH, DEVELOPMENT AND INNOVATION 2007–2013 (PNII) with the title: “Modulation of pro/anticarcinogenic effect of toxic chemical agents in breast cancer multitargeted therapy (CANCERTER-p53). Valentina Pileczki, Laura Pop, and Roxana Cojocneanu Petric has received a fellowships under the frame of European Social...
Funding: The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions
Conceived and designed the experiments: CB VP. Performed the experiments: LP RCP EP. Analyzed the data: CB SC RCP. Contributed reagents/materials/analysis tools: PAC IBN. Wrote the paper: CB PAC IBN.

References
1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H et al. (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6): 1374–403 doi: 10.1016/j.ejca.2012.12.027 PMID: 23458231
2. Pal SK, Childs BH, Pegram M (2011) Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 125(3): 627–36. doi: 10.1007/s10549-010-1293-1 PMID: 21161370
3. Chioerean R, Braicu C, Berindan-Neagoe I. (2013) Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth? Breast 22: 1026–33 doi: 10.1016/j.breast.2013.08.007 PMID: 24063766
4. Johnson R, Sabnis N, McConathy WJ, Lacko AG. (2013) The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer. Pharmaceutics 1: 5(2) doi: 10.3390/pharmaceutics5020329 PMID: 24300453
5. Yadav BS, Sharma SC, Chanana P, Jamb S. (2014) Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 5(2): 125–33. doi: 10.5306/wjco.v5i2.125 PMID: 24829859
6. Walerych D, Napoli M, Collavin L, Del Sal G. (2012) The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 33(11): 2007–17. doi: 10.1093/carcin/bgs232 PMID: 22822097
7. Freed-Pastor WA, Prives C. (2012) Mutant p53: one name, many proteins. Genes Dev 26(12): 1268–86 doi: 10.1101/gad.190678.112 PMID: 22713868
8. Liu K, Lou J, Wen T, Yin J, Xu B, Ding W, et al. (2013) Depending on the stage of hepatosteatosis, p53 causes apoptosis primarily through either DRAM-induced autophagy or BAX. Liver Int 33(10): 1566–74. PMID: 23875779
9. White E (2015) The role for autophagy in cancer. J Clin Invest 125(1): 42–6 doi: 10.1172/JCI73941 PMID: 25654549
10. Crichton D, Wilkinson S, O’Prey J, Syed N, Smith P, Harrison PR et al. (2006) DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 126: 121–34 PMID: 16839881
11. Dai F, Chen Y, Song Y, Huang L, Zhai D, Dong Y, et al. (2012) A natural small molecule harmine inhibits angiogenesis and suppresses tumour growth through activation of p53 in endothelial cells. PLoS One 7(12): e52162 doi: 10.1371/journal.pone.0052162 PMID: 23300602
12. Teodoro JG, Evans SK, Green MR (2007) Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med. 85: 1175–1186 PMID: 17589818
13. Kanwar J, Taskeen M, Mohammad I, Huo C, Chan TH, DouQP. (2012) Recent advances on tea polyphenols. Front Biosci (Elite Ed) 4: 111–31. PMID: 22201858
14. Sharma C, Nusri Oel-A, Begum S, Javed E, Rizvi TA, Hussain A (2012) (-)-Epigallocatechin-3-gallate induces apoptosis and inhibits invasion and migration of human cervical cancer cells. Asian Pac J Cancer Prev 13(9): 4815–25 PMID: 23167425
15. Suzuki Y, Miyoshi N, Isemura M (2012) Health-promoting effects of green tea. Proc Jpn Acad Ser B PhysBioSci 88(3): 88–101. PMID: 22450537
16. Tachibana H (2011) Green tea polyphenol sensing. Proc Jpn Acad Ser B PhysBioSci 87(3): 66–80. PMID: 21422740
17. Available: http://www.sabiosciences.com/pcrarraydataanalysis.php
18. Jiang Q, Li F, Shi K, Wu P, An J, Yang Y, Xu C (2014) Involvement of p38 in signal switching from autophagy to apoptosis via the PERK/eIF2α/ATF4 axis in selenite-treated NB4 cells. Cell Death Dis 5: e1270. doi: 10.1038/cddis.2014.200 PMID: 24874742
19. Braicu C, Pileczki V, Irimie A, Berindan-Neagoe I (2013) p53siRNA therapy reduces cell proliferation, migration and induces apoptosis in triple negative breast cancer cells. Mol Cell Biochem 381:61–8. doi: 10.1007/s11010-013-1688-5 PMID: 23881244

20. Berindan-Neagoe I, Braicu C, Irimie A (2012) Combining the chemotherapeutic effects of epigallocatechin 3-gallate with siRNA-mediated p53 knock-down results in synergic pro-apoptotic effects. Int J Nanomed 7: 6035–6047 doi: 10.2147/IJN.S36523 PMID: 23251091

21. Atencio I A, Grace M, Bordens R, Fritz M, Horowitz J A, Hutchins B, (2006) Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial Liver-directed p53 gene therapy clinical trial. Cancer Gene Therapy 13: 169–181, doi: 10.1038/sj.cgt.7700870 PMID: 16082381

22. Available: http://www.quarkpharma.com/qbi-en/products/qpi-1002da/; Accessed 2014 December.

23. Chen CA, Lo CK, Lin BL, Sibley E, Tang SC (2008) Application of doxorubicin-induced rAAV2-p53 gene delivery in combined chemotherapy and gene therapy for hepatocellular carcinoma. Cancer Biol Ther 7(2): 303–9 PMID: 18059187

24. Stervold GL, Andersen TI, Perou CM, Frengen E (2006) siRNA: a potential tool for future breast cancer therapy? Crit Rev Oncog 12(1–2):127–50.

25. Braicu C, Gherman C (2013) Epigallocatechingallate induce cell death and apoptosis in triple negative breast cancer cells Hs578T. J Drug Target. 21: 250–256

26. Chen WC, Hsu KY, Hung CM, Lin YC, Yang NS, Ho CT, et al. (2014) The anti-tumor efficiency of pterostilbene is promoted with a combined treatment of Fas signaling or autophagy inhibitors in triple negative breast cancer cells. Food Funct. 5(8):1856–65. doi: 10.1039/c4fo00145a PMID: 24944076

27. Chittaranjan S, Bortnik S, Dragowska WH, Xu J, Abeyesundara N, Leung A, et al. (2014) Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and-resistant triple-negative breast cancer. Clin Cancer Res. 20(12):3159–73. doi: 10.1158/1078-0432.CCR-13-2060 PMID: 24721646

28. Liu K, Shi Y, Guo XH, Ouyang YB, Wang SS, Liu DJ, et al. (2014) Phosphorylated AKT inhibits the apoptosis induced by DRAM-mediated mitophagy in hepatocellular carcinoma by preventing the translocation of DRAM to mitochondria. Cell Death Dis. 2014 Feb 20; 5:e1078. doi: 10.1038/cddis.2014.51 PMID: 24556693

29. Braicu C, Gherman CD, Irimie A, Berindan-Neagoe I. (2013) Epigallocatechin-3-Gallate (EGCG) inhibits cell proliferation and migratory behaviour of triple negative breast cancer cells. J Nanosci Nanotechnol. 13(1):632–7 PMID: 23646788